Assaf Gottlieb
Tel Aviv University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Assaf Gottlieb.
Molecular Systems Biology | 2014
Assaf Gottlieb; Gideon Y. Stein; Eytan Ruppin; Roded Sharan
Inferring potential drug indications, for either novel or approved drugs, is a key step in drug development. Previous computational methods in this domain have focused on either drug repositioning or matching drug and disease gene expression profiles. Here, we present a novel method for the large‐scale prediction of drug indications (PREDICT) that can handle both approved drugs and novel molecules. Our method is based on the observation that similar drugs are indicated for similar diseases, and utilizes multiple drug–drug and disease–disease similarity measures for the prediction task. On cross‐validation, it obtains high specificity and sensitivity (AUC=0.9) in predicting drug indications, surpassing existing methods. We validate our predictions by their overlap with drug indications that are currently under clinical trials, and by their agreement with tissue‐specific expression information on the drug targets. We further show that disease‐specific genetic signatures can be used to accurately predict drug indications for new diseases (AUC=0.92). This lays the computational foundation for future personalized drug treatments, where gene expression signatures from individual patients would replace the disease‐specific signatures.
Molecular Systems Biology | 2012
Assaf Gottlieb; Gideon Y. Stein; Yoram Oron; Eytan Ruppin; Roded Sharan
Inferring drug–drug interactions (DDIs) is an essential step in drug development and drug administration. Most computational inference methods focus on modeling drug pharmacokinetics, aiming at interactions that result from a common metabolizing enzyme (CYP). Here, we introduce a novel prediction method, INDI (INferring Drug Interactions), allowing the inference of both pharmacokinetic, CYP‐related DDIs (along with their associated CYPs) and pharmacodynamic, non‐CYP associated ones. On cross validation, it obtains high specificity and sensitivity levels (AUC (area under the receiver‐operating characteristic curve)⩾0.93). In application to the FDA adverse event reporting system, 53% of the drug events could potentially be connected to known (41%) or predicted (12%) DDIs. Additionally, INDI predicts the severity level of each DDI upon co‐administration of the involved drugs, suggesting that severe interactions are abundant in the clinical practice. Examining regularly taken medications by hospitalized patients, 18% of the patients receive known or predicted severely interacting drugs and are hospitalized more frequently. Access to INDI and its predictions is provided via a web tool at http://www.cs.tau.ac.il/∼bnet/software/INDI, facilitating the inference and exploration of drug interactions and providing important leads for physicians and pharmaceutical companies alike.
Journal of Computational Biology | 2011
Liat Perlman; Assaf Gottlieb; Nir Atias; Eytan Ruppin; Roded Sharan
Understanding drugs and their modes of action is a fundamental challenge in systems medicine. Key to addressing this challenge is the elucidation of drug targets, an important step in the search for new drugs or novel targets for existing drugs. Incorporating multiple biological information sources is of essence for improving the accuracy of drug target prediction. In this article, we introduce a novel framework--Similarity-based Inference of drug-TARgets (SITAR)--for incorporating multiple drug-drug and gene-gene similarity measures for drug target prediction. The framework consists of a new scoring scheme for drug-gene associations based on a given pair of drug-drug and gene-gene similarity measures, combined with a logistic regression component that integrates the scores of multiple measures to yield the final association score. We apply our framework to predict targets for hundreds of drugs using both commonly used and novel drug-drug and gene-gene similarity measures and compare our results to existing state of the art methods, markedly outperforming them. We then employ our framework to make novel target predictions for hundreds of drugs; we validate these predictions via curated databases that were not used in the learning stage. Our framework provides an extensible platform for incorporating additional emerging similarity measures among drugs and genes. Supplementary Material is available at www.liebertonline.com/cmb.
Cell | 2014
Robert Durruthy-Durruthy; Assaf Gottlieb; Byron H. Hartman; Jörg Waldhaus; Roman D. Laske; Russ B. Altman; Stefan Heller
The otocyst harbors progenitors for most cell types of the mature inner ear. Developmental lineage analyses and gene expression studies suggest that distinct progenitor populations are compartmentalized to discrete axial domains in the early otocyst. Here, we conducted highly parallel quantitative RT-PCR measurements on 382 individual cells from the developing otocyst and neuroblast lineages to assay 96 genes representing established otic markers, signaling-pathway-associated transcripts, and novel otic-specific genes. By applying multivariate cluster, principal component, and network analyses to the data matrix, we were able to readily distinguish the delaminating neuroblasts and to describe progressive states of gene expression in this population at single-cell resolution. It further established a three-dimensional model of the otocyst in which each individual cell can be precisely mapped into spatial expression domains. Our bioinformatic modeling revealed spatial dynamics of different signaling pathways active during early neuroblast development and prosensory domain specification.
PLOS Genetics | 2013
Gal Hagit Romano; Yaniv Harari; Tal Yehuda; Ariel Podhorzer; Linda Rubinstein; Ron Shamir; Assaf Gottlieb; Yael Silberberg; Dana Pe'er; Eytan Ruppin; Roded Sharan; Martin Kupiec
Telomeres protect the chromosome ends from degradation and play crucial roles in cellular aging and disease. Recent studies have additionally found a correlation between psychological stress, telomere length, and health outcome in humans. However, studies have not yet explored the causal relationship between stress and telomere length, or the molecular mechanisms underlying that relationship. Using yeast as a model organism, we show that stresses may have very different outcomes: alcohol and acetic acid elongate telomeres, whereas caffeine and high temperatures shorten telomeres. Additional treatments, such as oxidative stress, show no effect. By combining genome-wide expression measurements with a systematic genetic screen, we identify the Rap1/Rif1 pathway as the central mediator of the telomeric response to environmental signals. These results demonstrate that telomere length can be manipulated, and that a carefully regulated homeostasis may become markedly deregulated in opposing directions in response to different environmental cues.
BMC Medicine | 2013
Assaf Gottlieb; Gideon Y. Stein; Eytan Ruppin; Russ B. Altman; Roded Sharan
BackgroundClinical decision support systems assist physicians in interpreting complex patient data. However, they typically operate on a per-patient basis and do not exploit the extensive latent medical knowledge in electronic health records (EHRs). The emergence of large EHR systems offers the opportunity to integrate population information actively into these tools.MethodsHere, we assess the ability of a large corpus of electronic records to predict individual discharge diagnoses. We present a method that exploits similarities between patients along multiple dimensions to predict the eventual discharge diagnoses.ResultsUsing demographic, initial blood and electrocardiography measurements, as well as medical history of hospitalized patients from two independent hospitals, we obtained high performance in cross-validation (area under the curve >0.88) and correctly predicted at least one diagnosis among the top ten predictions for more than 84% of the patients tested. Importantly, our method provides accurate predictions (>0.86 precision in cross validation) for major disease categories, including infectious and parasitic diseases, endocrine and metabolic diseases and diseases of the circulatory systems. Our performance applies to both chronic and acute diagnoses.ConclusionsOur results suggest that one can harness the wealth of population-based information embedded in electronic health records for patient-specific predictive tasks.
Journal of Computational Biology | 2012
Yael Silberberg; Assaf Gottlieb; Martin Kupiec; Eytan Ruppin; Roded Sharan
Elucidating signaling pathways is a fundamental step in understanding cellular processes and developing new therapeutic strategies. Here we introduce a method for the large-scale elucidation of signaling pathways involved in cellular response to drugs. Combining drug targets, drug response expression profiles, and the human physical interaction network, we infer 99 human drug response pathways and study their properties. Based on the newly inferred pathways, we develop a pathway-based drug-drug similarity measure and compare it to two common, gold standard drug-drug similarity measures. Remarkably, our measure provides better correspondence to these gold standards than similarity measures that are based on associations between drugs and known pathways, or on drug-specific gene expression profiles. It further improves the prediction of drug side effects and indications, elucidating specific response pathways that may be associated with these drug properties. Supplementary Material for this article is available at www.liebertonline.com/cmb.
Bioinformatics | 2011
Assaf Gottlieb; Igor Berman; Eytan Ruppin; Roded Sharan
SUMMARY PRINCIPLE is a Java application implemented as a Cytoscape plug-in, based on a previously published algorithm, PRINCE. Given a query disease, it prioritizes disease-related genes based on their closeness in a protein-protein interaction network to genes causing phenotypically similar disorders to the query disease. AVAILABILITY Implemented in Java, PRINCIPLE runs over Cytoscape 2.7 or newer versions. Binaries, default input files and documentation are freely available at http://www.cs.tau.ac.il/~bnet/software/PrincePlugin/. CONTACT [email protected]; [email protected].
Clinical Pharmacology & Therapeutics | 2014
Assaf Gottlieb; Russ B. Altman
There are significant gaps in our understanding of the pathways by which drugs act. This incomplete knowledge limits our ability to use mechanistic molecular information rationally to repurpose drugs, understand their side effects, and predict their interactions with other drugs. Here, we present DrugRouter, a novel method for generating drug‐specific pathways of action by linking target genes, disease genes, and pharmacogenes using gene interaction networks. We construct pathways for more than a hundred drugs and show that the genes included in our pathways (i) co‐occur with the query drug in the literature, (ii) significantly overlap or are adjacent to known drug‐response pathways, and (iii) are adjacent to genes that are hits in genome‐wide association studies assessing drug response. Finally, these computed pathways suggest novel drug‐repositioning opportunities (e.g., statins for follicular thyroid cancer), gene–side effect associations, and gene–drug interactions. Thus, DrugRouter generates hypotheses about drug actions using systems biology data.
Journal of Medical Internet Research | 2015
Assaf Gottlieb; Robert Hoehndorf; Michel Dumontier; Russ B. Altman
Background There is no publicly available resource that provides the relative severity of adverse drug reactions (ADRs). Such a resource would be useful for several applications, including assessment of the risks and benefits of drugs and improvement of patient-centered care. It could also be used to triage predictions of drug adverse events. Objective The intent of the study was to rank ADRs according to severity. Methods We used Internet-based crowdsourcing to rank ADRs according to severity. We assigned 126,512 pairwise comparisons of ADRs to 2589 Amazon Mechanical Turk workers and used these comparisons to rank order 2929 ADRs. Results There is good correlation (rho=.53) between the mortality rates associated with ADRs and their rank. Our ranking highlights severe drug-ADR predictions, such as cardiovascular ADRs for raloxifene and celecoxib. It also triages genes associated with severe ADRs such as epidermal growth-factor receptor (EGFR), associated with glioblastoma multiforme, and SCN1A, associated with epilepsy. Conclusions ADR ranking lays a first stepping stone in personalized drug risk assessment. Ranking of ADRs using crowdsourcing may have useful clinical and financial implications, and should be further investigated in the context of health care decision making.